What's happening?

news2

Published November 8, 2016

XSpray’s new share issue oversubscribed

Stockholm, Sweden, November 8, 2016 – XSpray Microparticles AB, a clinical stage product development company that creates improved and generic versions of existing cancer products, today announced the successful completion of a new share issue of SEK 41 million. “I’m…

Read More »
news2

Published October 2, 2015

XSpray Microparticles receives 18 million SEK investment

STOCKHOLM – October 2, 2015  The 18 million SEK investment will be used to finance the clinical development of XSpray’s lead compound, XS-004, developed with XSpray’s proprietary HyNap™ drug formulation technology. XS-004 is based on a well-known protein kinase inhibitor…

Read More »
news2

Published March 10, 2015

Meet XSpray at Advanced Drug Delivery Approaches for Small & Large Molecules, April 30, 2015, United Kingdom

THURSDAY, April 30, 2015
Bracknell, United Kingdom

Read More »
news2

Published May 8, 2014

XSpray Announces Positive Phase I Data for HyNap™ Nilotinib

XSpray’s proprietary HyNap™ formulation of nilotinib demonstrated significantly improved uptake and reduced food interaction in a Phase I clinical trial compared to previously reported data for the commercial available formulation of nilotinib.

Read More »
news4

Published September 23, 2013

XSpray CEO explains the HyNap platform for PKIs

XSpray’s proprietary HyNap™ formulation technology has consistently shown major improvements in solubility and improved bioavailability for all to date tested small molecule protein kinase inhibitors. This is a surprising achievement considering that such compatibility with a whole class of compounds are very…

Read More »
news2

Published October 10, 2012

XSpray Announces Major Advance in the Formulation of Challenging Oral Protein Kinase Inhibitors (PKI)

XSpray announces positive data from dog studies with their novel formulation strategy for PKIs.

Read More »